share_log

Anixa Biosciences Analyst Ratings

Anixa Biosciences Analyst Ratings

Anixa 生物科學分析師評級
Benzinga ·  2023/09/18 12:18
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
09/18/2023 259.28% HC Wainwright & Co. → $12 Reiterates Buy → Buy
08/29/2023 259.28% HC Wainwright & Co. → $12 Reiterates Buy → Buy
07/28/2023 259.28% HC Wainwright & Co. → $12 Reiterates Buy → Buy
07/12/2023 259.28% HC Wainwright & Co. → $12 Reiterates Buy → Buy
06/19/2023 259.28% HC Wainwright & Co. → $12 Reiterates Buy → Buy
05/23/2023 259.28% HC Wainwright & Co. → $12 Reiterates Buy → Buy
04/18/2023 259.28% HC Wainwright & Co. → $12 Reiterates → Buy
04/18/2023 169.46% Chardan Capital → $9 Reiterates → Buy
03/23/2023 259.28% HC Wainwright & Co. $11 → $12 Maintains Buy
03/22/2023 169.46% Chardan Capital $8 → $9 Maintains Buy
02/28/2023 229.34% HC Wainwright & Co. → $11 Reiterates → Buy
12/23/2022 139.52% Chardan Capital → $8 Initiates Coverage On → Buy
04/12/2021 229.34% HC Wainwright & Co. → $11 Initiates Coverage On → Buy
03/23/2020 154.49% Aegis Capital → $8.5 Initiates Coverage On → Buy
12/30/2019 139.52% B. Riley Securities $11.25 → $8 Maintains Buy
日期 上行/下行 分析公司 目標價格變化 評級變化 上一次/當前評級
09/18/2023 259.28% HC Wainwright公司 →$12 重申 購買→購買
2023年08月29日 259.28% HC Wainwright公司 →$12 重申 購買→購買
07/28/2023 259.28% HC Wainwright公司 →$12 重申 購買→購買
07/12/2023 259.28% HC Wainwright公司 →$12 重申 購買→購買
2023/06/19 259.28% HC Wainwright公司 →$12 重申 購買→購買
2023年05月23日 259.28% HC Wainwright公司 →$12 重申 購買→購買
04/18/2023 259.28% HC Wainwright公司 →$12 重申 →購買
04/18/2023 169.46% 查爾丹資本 →$9 重申 →購買
03/23/2023 259.28% HC Wainwright公司 $11→$12 維護
03/22/2023 169.46% 查爾丹資本 $8→$9 維護
02/28/2023 229.34% HC Wainwright公司 →$11 重申 →購買
2022年12月23日 139.52% 查爾丹資本 →$8 開始承保 →購買
04/12/2021 229.34% HC Wainwright公司 →$11 開始承保 →購買
03/23/2020 154.49% 宙斯盾資本 →$8.5 開始承保 →購買
2019年12月30日 139.52% B.萊利證券 $11.25→$8 維護

What is the target price for Anixa Biosciences (ANIX)?

Anixa Biosciences(ANIX)的目標價格是多少?

The latest price target for Anixa Biosciences (NASDAQ: ANIX) was reported by HC Wainwright & Co. on September 18, 2023. The analyst firm set a price target for $12.00 expecting ANIX to rise to within 12 months (a possible 259.28% upside). 12 analyst firms have reported ratings in the last year.

阿尼克斯生物科學公司(納斯達克代碼:ANIX)的最新目標價是由HC Wainwright&Co.於2023年9月18日報道的。這家分析公司將目標價定為12美元,預計ANIX將在12個月內上漲至(可能上漲259.28%)。去年有12家分析公司公佈了評級。

What is the most recent analyst rating for Anixa Biosciences (ANIX)?

Anixa Biosciences(ANIX)的最新分析師評級是多少?

The latest analyst rating for Anixa Biosciences (NASDAQ: ANIX) was provided by HC Wainwright & Co., and Anixa Biosciences reiterated their buy rating.

分析師對Anixa Biosciences(納斯達克代碼:ANIX)的最新評級由HC Wainwright&Co.提供,Anixa Biosciences重申買入評級。

When is the next analyst rating going to be posted or updated for Anixa Biosciences (ANIX)?

Anixa Biosciences(ANIX)的下一次分析師評級將於何時發佈或更新?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Anixa Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Anixa Biosciences was filed on September 18, 2023 so you should expect the next rating to be made available sometime around September 18, 2024.

分析師在進行了廣泛的研究後得出了股票評級,其中包括查閱公開財務報表,與Anixa Biosciences的高管和客戶交談,以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次,所以你每年應該會得到每家公司每家公司的4個評級。Anixa Biosciences的上一次評級是在2023年9月18日提交的,所以你應該預計下一次評級將在2024年9月18日左右提供。

Is the Analyst Rating Anixa Biosciences (ANIX) correct?

分析師對Anixa Biosciences(ANIX)的評級正確嗎?

While ratings are subjective and will change, the latest Anixa Biosciences (ANIX) rating was a reiterated with a price target of $0.00 to $12.00. The current price Anixa Biosciences (ANIX) is trading at is $3.34, which is within the analyst's predicted range.

雖然評級是主觀的,並將發生變化,但最新的Anixa Biosciences(ANIX)評級被重申,目標價在0.00美元至12.00美元之間。目前Anixa Biosciences(ANIX)的交易價格為3.34美元,在分析師的預測範圍內。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論